REVIEW OF PULMONARY EMBOLISM by K. Gayathri et al.
Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 838 - 846 
 
 
This article can be downloaded from www.ijpbs.net 
P - 838 
Review Article                                                                                                                      Pharmacology 
 
 
 
 
 
 
International Journal of Pharma and Bio Sciences  ISSN 
0975-6299 
 
REVIEW OF PULMONARY EMBOLISM 
 
K. GAYATHRI DEVI*
 AND G. VAMSI KRISHNA MURTHY. 
 
 Department of pharmaceutical analysis, MAM college of pharmacy, Guntur (dist). 
 
ABSTRACT 
 
Pulmonary embolism is a blockage of main artery or one of its branches of lung by the 
fat, amniotic fluid, embolisation of air or any other foreign substances. It is also due to 
formation  of  thrombus  [blood  clot]  in  the  arteries  of  lung.  Due  to  the  pulmonary 
embolism the blood circulation in the body will be effected. Sometimes PE leads to 
death also by the lacking of breathing. In USA the annual incidence rates per 1000 
persons  aged  65-69  are  1.3  affected  by  pulmonary  embolism.  The  diagnosis  of 
pulmonary embolism at the earlier stage will be difficult because the symptoms like 
difficulty  in  breathing  and  chest  pain  are  not  easily  differentiated  from  the  other 
diseases  like  myocardial  infarction.  The  usage  of  drugs  like  anti  coagulants  and 
thrombolytic  cause  bleeding  problems  even  though  they  shows  the  antagonistic 
activity  of  pulmonary  embolism  at  higher  doses.  Physician  responsibility  is  to 
successfully  avoid  bleeding  disorders  are  at  the  time  of  prevention  of  pulmonary 
embolism. And also by conducting of programs which should strive to coordinate care 
, by region wide guidelines  and  by implementing of care programs  there is a chance  
to  elaborate  knowledge  about  the  pulmonary  embolism  to  the  physicians  and  also 
there is a chance to bring awareness among the public  which may decreases the 
number deaths due to pulmonary embolism annually. 
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INTRODUCTION 
 
Pulmonary  embolism  [PE] is  a  blockage of 
the  main  artery  of  the  lung  or  one  of  the 
branches  by a substance. That has travels 
to  the  body  through  the  blood  stream 
[embolism]
1. Pulmonary embolism is a blood 
clot  in  the  lung.  It  usually  comes  from 
smaller  vessels  in  the  leg,  pelvis,  arm  [or] 
heart when a clot forms in the legs or arms it 
is referred to as a deep venous thrombosis 
[DVT]
2. Usually this is due to embolism of a 
thrombus [blood clot] from the deep process 
termed venous thrombo embolism. A small 
proportion is due to the embolization of air, 
fat or amniotic fluid. The blood flow through 
the lungs and the resultant pressure on the 
right  ventricle  of  the  heart  leads  to  the 
symptoms  and  signs.  Pulmonary  embolism 
is  increased  in  various  situations  such  as 
cancer and prolonged bed rest
1. 
 
ETIOLOGY  
Although the blood clot is the most common 
cause of PE. Air, fat, bone marrow, foreign 
bodies,  arthroplasty,  cement,  tumor  cells 
also  can  obstruct  the  pulmonary  vessels. 
Bed rest and inactivity pose the greatest risk 
for developing deep vein thrombosis. Certain 
medical  conditions  common  among  the 
elderly [e.g.; trauma to leg vessels, obesity, 
heart failure malignancy, hip fracture myelo 
proliferative  disorders  ] predispose them to 
venous thrombosis as do smoking estrogen 
use,  stamoxifen  [synthetic,  anti  estrogenic 
compound  ]  therapy,  the  presence  of  a 
femoral  venous  catheter  surgery  and 
immobility.  Risk  factors  for  venous 
thrombosis are vessel wall injury, stasis and 
conditions that increase the tendency of the 
blood  to  clot  including  rare  deficiencies  of 
anti  thrombin  III,  protein  c  and  proteins  as 
well  as  disseminated  intravascular 
coagulation.  Polycythemia  vera,  the 
presence  of  a  lupus  anticoagulant  or  anti 
phosphor  lipid  antibodies.  Aging  is  also 
associated  with  increased  coagulation  and 
products  of  fibrinolysis,  resulting  in  an 
overall  pre  thrombotic  state.  About  90%  of 
blood clots that cause pulmonary embolism 
originate in the legs. the risk that a clot will 
embolize the lodge in the lungs is greater if 
the clot is in the popliteal or iliofemoral vein 
[about 50%] than if it is confined to the calf 
veins  [<5%]  less  common  sites  of 
thrombosis  that  may  leads  to  PE  are  the 
right  atrium,  right  ventricle,  and  the  pelvic, 
renal, hepatic, subclavin and jugular veins
3. 
 Mainly the major risk factors for PE are of; 
1. Stasis.  
2. Endothelial injury. 
3. Hypercoagulable states.  
Most thrombi are derived from the veins of 
the thigh but can arise from mural [pertaining 
to  the  wall  of  cavity,  organ  [or]  vessel  ] 
thrombi in the right side of the heart, surgical 
procedure  that  risk  intimal  injury  are 
common causes  of PE.  Bedridden  patients 
subject to long period of stasis are also at 
risk.  Deep  vein  thrombosis  [DVT]  is  not 
definitively associated with the occurrence of 
pulmonary embolism. PE also rarely results 
from  emobilization  of  tumor  cells  or 
fragments,  fat,  amniotic  fluids,  foreign 
bodies,  or  air
2.  Bed  rest  and  confinement 
without  walking,  even  for  a  few  hours,  are 
common precipitators
4. 
 
PREVALENCE 
PE  affects  an  estimated  117  people  per 
100,000  persons  yearly,  resulting  in  about 
350,000  cases  yearly  and  causes  up  to 
85,000  deaths  yearly.  PE  affects  mainly 
adults.  In  USA  pulmonary  emboli  and  its 
primary  cause  deep  vein  thrombosis  are 
estimated to lead to 110,000 hospitalizations 
annually  in  patients  more  than  65  years. 
Annual  incidence  rates  per  1000  persons 
aged  65-69  are  1.3  and  1.8  for  pulmonary 
emboli and deep vein thrombi respectively. 
Both  rates  increase  with  age.  Pulmonary 
embolism is highly fatal and 32% of cases, 
they are not diagnosed until after they cause 
death
4.  If  untreated  pulmonary  embolism 
has  a  high  mortality  and  accounts  for  55-
10%  all  in  hospital  deaths
4,5. Registry  data 
shows  an  overall  3  months  mortality  of 
17.4%
6 of these deaths 45% were ascribed 
to  PE  and  755  occurred  during  the  initial 
hospital admission for PE 
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SYMPTOMS 
Symptoms of PE are sudden onset dyspnea  
[shortness  of  breath  ],  tachypnea    [rapid 
breathing  ],  chest  pain  of  a  worsened  by 
breathing, cough, hemoptysis, [coughing up 
blood ] more severe cases can include signs 
such as discoloration, usually of the lips and 
fingers
1.  Patients  who  have  small  thrombo 
emboli  may  be  asymptomatic  or  have 
atypical symptoms.  Non specific symptoms 
suggestive  of  pulmonary  emboli  in  the 
elderly  include  persistent  low-grade  fever, 
change in mental status, or a clinical picture 
that mimics air  way  infection. Patients with 
PE usually present with one of the following 
symptoms patterns 
1.  Diagnostically  confusing  syndromes 
[confusion, unexplained fever, wheezing, 
resistant.  .heart  failure,  unexplained 
arrhythmias]. 
2.   Transient  shortness  of  breath  and 
tachypnea. 
3.  Pulmonary  infraction  [pleuritic  pain, 
cough,  hemoptysis,  pleural  infusion, 
pulmonary …..Infiltrate]. 
4.  Right  side  heart  failure  along  with 
shortness  of  breath  and  tachypnea 
secondary to ….pulmonary embolism [or] 
5. Cardiovascular collapse with hypotension 
and syncope. 
The most common physical findings are leg 
edema,  tenderness  cyanosis,  and  pleural 
friction  rub,  ,increased  warmth,  Oman’s 
sign
3. 
 
CAUSES 
Causes for PE are multifractorial and are as 
follows 
1.  Venous  stasis:  Venous  stasis  leads  to 
accumulation  of  platelets  and  thrombin  in 
veins. 
2.  Hypercoagulable  states:  The  complex  and 
delicate  balance  between  coagulation  and 
anti  coagulation  is  altered  by  many 
diseases,  by  obesity,  after  surgery,  or  by 
trauma. 
Hypercoagulable states may be acquired or 
congenital.  Factor-V  Leiden  mutation 
causing resistance to activated protein c is 
most  common  risk  factor.  And  is  most 
common cause of familial thromboembolism. 
3. Immobilization: Leads to local venous stasis 
by accumulation of clotting factors and fibrin 
resulting in thrombus formation. 
4.  Surgery  and  trauma:  Both  surgical 
accidental  trauma  predispose  patients  to 
venous  thrombo  embolism  by  activating 
clotting  factors  and  causing  immobility. 
Severe burns carry a high risk of DVP or PE. 
5.  Pregnancy:  The  incidence  of  thrombo 
embolic  disease  in  pregnancy  has  been 
reported  to  range  from  1  case  in  2oo 
deliveries to 1 case in 1400 deliveries. 
6. Oral contraceptives and estrogen replacement: 
Estrogen  containing  birth  control  pills  have 
increased the occurrence of venous thrombo 
embolism in healthy women. 
7.  Malignancy:  The  neoplasm’s  most 
commonly  associated  with  PE,  in 
descending  order  of  frequency,  are 
pancreatic  carcinoma  bronchogenic 
carcinoma, carcinomas of the genitourinary 
tract, colon, stomach and breast. 
Travel of 4 hours or more in the past month, 
surgery within the last 3 months, current or 
past  history  of  thrombo  phlebitis,      central 
venous  instrumentation  with  in  past  3 
months  ,  paralysis,  varicose  veins  , 
inflammatory bowel disease. 
 
PATHOPHYSIOLOGY 
Once DVT develops, clots may dislodge and 
travel through the venous system and right 
side of the heart to lodge in the pulmonary 
arteries,  where  they  partially  or  completely 
occlude  one  or  more  vessels.  The 
consequence  depend  on  the  size  and 
number  of  emboli,  the  pulmonary  reaction, 
the under laying condition of the lungs, and 
the ability of the body’s intrinsic thrombolytic 
system to dissolve clots. Small emboli may 
have  no  acute  physiologic  effects;  many 
begin  to  lyses  immediately  and  resolve 
within  hours  or  days.  Larger  emboli  can 
cause  a  reflex  increase  in  ventilation 
[tachypnea],    hypoxemia  from 
ventilation/perfusion    [V/Q]  mismatch, 
shunting,  and  low  mixed  venous  oxygen 
content  as  a  result  low  cardiac  output, 
telecasts  from  alveolar  hypomania  and 
abnormalities in surfactant, and an increase 
in pulmonary vascular resistance caused by 
mechanical  obstruction  and Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 838 - 846 
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vasoconstriction.  Endogenous  lyses  reduce 
most  emboli,  even  those  of  modulate  size, 
without  treatment  and  physiologic  attritions 
decrease over hours or days, some emboli 
resist  lyses  and  may  organize  and  persist 
occasionally,  chronic  residual  obstruction 
leads  to  pulmonary  hypertension  [chronic 
thrombo  embolic  hypertension]  that  may 
develop  over  years  and  result  in  chronic 
right  heart  failure.  When  large  emboli 
occlude major arteries, or when many small 
emboli  occlude  >50%  of  the  distal  arterial 
system,  right  ventricular  system  increases, 
causing acute right ventricular failure, failure 
with shock [massive PE] or sudden death in 
severe cases. Risk factors for death include 
age >70 years, cancer and COPD. The risk 
of death depends on the degree and rate of 
rise  of  right  sided  pressures  and  on  the 
patients  underlying  cardiopulmonary  status 
higher pressures more healthy patients with 
pre  existing  cardio  pulmonary  disease. 
Otherwise healthy patients may survive a PE 
that  occludes  >50%  of  pulmonary  vascular 
bed. Pulmonary infraction occurs in<10% of 
patients  diagnosed  with  PE.  This  low  rate 
has been attributed to the dual blood supply 
to the lungs [i.e.; bronchial and pulmonary. 
A thrombus that has separated from 
its  site  of  origin  travels  through  the 
circulation  to  the  inferior  vena  cava.  The 
right  ventricle  pumps  this  thrombus  to  the 
pulmonary  arteries,  the  thrombus  finally 
lodges’  may  occur  singly  or  multiply.  They 
can be microscopic in size or be big enough 
to  occlude  the  major  branches  of  the 
pulmonary artery. PE sometimes may leads 
to corpulmonale. The most important patho 
physiological  consequence  of  PE  is  V/Q 
mismatch in which there is “DEAD SPACE” 
ventilation  in  some  parts  of  the  lung  and 
over  perfusion  in  others.  ”dead  space” 
ventilation  refers  to  ventilation  of  lung 
segments  that  have  obstructed  vascular 
supply  and  thus  no  perfusion  on  the  other 
hand.  Over  perfusion  and  decreased 
vascular resistance in other part of the lung 
leads to right-to-left intra pulmonary shunting 
with  insufficient  oxygenation  of  a  large 
portion of per fused blood
2.  
 
 
DIAGNOSIS 
Diagnosis  of  PE  is  based  primarily  on 
validated  clinical  criteria  combined  with 
selective  testing  because  the  typical 
cleanliness of breath, chest pain cannot be 
definitively  differentiated  from  other  causes 
of  chief  pain  and  shortness  of  breath. 
Clinical imaging is usually based on clinical 
grounds i.e.; the medical history, symptoms 
and  findings  on  physical  examination 
assessment of clinical probability
1. 
 
BLOOD TEST 
Early  primary  research  has  shown  that  in 
low/moderate  suspicion  of  PE  a  normal  D-
dimmer  level  (shown  in  blood  test)  is  the 
possibility  of  thrombotic  PE
8.  PE  is  being 
suspected a number of blood test is done, in 
order to exclude important secondary cause 
of  PE.  This  blood  count,  clotting  status 
(PT,APTT,TT),  and  some  screening  tests 
(erythrocyte  sedimentation  rate,  renal 
function  if  one  of  this  is  abnormal,  further 
investigation be warranted. Standard test for 
diagnosing  pulmonary  embolism  is 
pulmonary  angiography
9.  Specific 
appearance  of  the  right  ventricle  on 
echocardiography  is  referred  as  the  mc 
Connelly’s sign. This is the finding the free 
wall  but  normal  motion  of  the  apex.  This 
phenomenon  has  77%  sensitivity  and  94% 
specificity for the diagnosis of embolism
10. 
Electrocardiogram  (ECG)  is  routinely 
done on patients with chest pain to quickly 
diagnose myocardial infractions. Heart may 
show  signs  of  right  heart  strain  or  acute 
corpulmonale  in  cases  of  large  PE.  the 
classic signs are large S wave in lead-III and 
an inverted T wave in lead-III (“SIQ3T3”)
 11. 
This is occasionally (up to 20%) present, but 
may also lung conditions and has therefore 
limited  diagnostic  value.  The  most 
commonly seen signs in the ECG are sinus 
axis  deviation  and  right  bundle  branch 
block
12. 
 
TREATMENT 
Drugs used to treat pulmonary embolism are of ;  
1.Anticoagulants                          
2.Thrombolytics 
1. Anticoagulants Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 838 - 846 
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These drugs show mechanism of action by 
preventing the coagulation formation [or] by 
dissolving the already formed coagulations. 
The  drugs  under  this  category  are  mainly   
A. Heparin   
B. Warfarin 
A. Heparin: Mainly two forms of heparin are 
used they are      
1. Unfractioned heparin                 
2. Low molecular weight heparin. 
 
1.  Unfractioned heparin 
It is administered in the hospital only, to the 
patients is given continuously through I.V but 
can also be given as an injection under skin. 
Frequent  blood  tests  [usually  6  hours]  are 
required to monitor the clotting effects of this 
medicine. 
Mechanism of action: 
It  shows  mechanism  of  action  by  in 
activating the thrombin and activated factor 
X  [factor  Xa]  through  an  antithrombin  [AT] 
dependent mechanism. Heparin binds to the 
AT  through  a  high  affinity  polysaccharide, 
which  present  on  about  a  third  of  heparin 
molecule. For inhibition of thrombin, heparin 
must  bind  to  the  coagulation  enzyme 
antithrombin,  where  as  binding  to  the 
enzyme is not required for inhibition of factor 
Xa. Molecules of heparin with fewer than 18 
sachharides lack the chain length of bridge 
between  thrombin  &  AT,  therefore  are 
unable to inhibit thrombin. in contrast, very 
small  heparin  fragments  containing  the 
polysaccharide  sequence  inhibit  factor  Xa 
via AT by inactivating thrombin heparin not 
only  prevents  thrombin  but  also  inhibits 
thrombin  induced  activation  of  platelets 
factors V and VIII
14. 
 
Adverse effect: 
Thrombocytopenia,  osteopenia, 
hemorrhage, thrombosis, osteoporosis, hypo 
aldosteronism  and  hypersensitivity 
reactions
14. 
 
2. Low Molecular Weight Heparin [LMWH] 
They increase the action of anti thrombin III 
on factor Xa but not its action on thrombin, 
because the molecules are too small to bind 
to  both  enzyme  and  inhibitor.essential  for 
inhibition  of  thrombin  but  not  for  that  of 
factorXa. The LMWH is more affective more 
than  the  UFH.  The  LMWH  is 
usually.preferred because it can be given as 
an injection once or twice per a day and is 
given  at  home  itself.  Blood  tests  are  not 
need to monitor LMWH clotting effects
14. 
 
Mechanism of action 
Compared with UFH, LMWH’s have reduced 
ability  to  inactivate  thrombin  because  the 
smaller  fragments  cannot  bind 
simultaneously  to  antithrombin.  In.contrast 
because bridging between antithrombin and 
Xa  factor  is  less  critical  for  antifactor  Xa 
activity,  the  smaller  fragments  inactivate 
factor  Xa  almost  as  well  as  do  large 
molecules.  because  virtually  all  heparin 
molecules  contains  at  least  18 
polysaccharide units UFH has an antifactor 
Xa,  anti  factor  II  a  ratio  of  1:1.in  contrast 
commercial LMWH’s have anti factor Xa to 
anti  factor  II  a  ratio  between  2:1  and  4:1 
depending  on  their  molecular  size 
distribution.  Reduced  binding  to  plasma  to 
plasma proteins and cells is responsible for 
the  more  predictable  dose  response 
relationship of LMWH, longer plasma half life 
[compared  with  UFH]  the  lower  risk  of 
heparin  induced  thrombocytopenia  and 
octopenia.  LMWH’s  are  cleared  principally 
by the renal route
16. 
 
Treatment of venous thrombo embolism 
LMWH’s re administered in weight adjusted 
doses by S.C injection and are not moniterd. 
Depending on the LMWH agent, a dose of 
100 antifactor Xa units per Kg twice daily or 
of 150-200 antifactor Xa units per Kg daily is 
given. Although laboratory monitoring is not 
usually  required,  the  antifactor  Xa  level 
should  be  checked  in  patients  with  renal 
insufficiency, morbid obesity, and pregnancy 
because  the  pharmacokinetic  properties, 
efficacy  and  safety  of  LMWH  are  not  well 
established  in  these  situations.  LMWH 
preparations are at least as affective as and 
safe  as  intravenous  heparin  for  the 
treatment of DVT and PE, and the rates of 
recurrent  thrombo  embolism  and  major 
bleeding  are  similar  with  all  of  the  LMWH 
preparations that have been evaluated out of 
hospital  administration of LMWH to eligible 
patients with DVT is as affective and safe as Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 838 - 846 
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intravenous heparin administered in hospital 
ones  daily  administration  of  two  different 
LMWH    preparations  is  as  safe  as  twice 
daily  dosing.  The  risk  of  bleeding  with 
LMWH is small and comparable to that with 
low-dose  UFH.  Low  doses  of  LMWH 
administered S.C ones daily are at least as 
affective  and  safe  as  low  dose  UFH 
administered S.C 2 or 3 times daily
16. 
 
B. Warfarin 
Warfarin  is  taken  in  pill  form.  When  the 
warfarin  is  at  a  proper  level  heparin  is 
discontinued  and  treatment  with  warfarin 
continues.  warfarin  reduces  the  risk  of 
another blood clot [after PE 3 or 6 months ] 
warfarin  is  also  be  known  as  vitamin  K 
antagonists [reflecting the structural between 
warfarin and vitamin K] their effects several 
days to develop because of the time taken 
for  degradation  of  performed  carboxylated 
clotting  factors.  Their  onset  of  action  thus 
depends on the elimination half lives of the 
relevant factors. Factor VII with a half life of  
6 hours is effected first then IX, X and II with 
half  lives  of  24,  40  and  60  hours 
respectively
13. 
 
Adverse effect                                              
Hemorrhage  [especially  into  the  bowel  [or] 
the  brain].  The  warfarin  shows  the  activity 
lately  after  administration than the  heparin. 
Heparin  shows  the  clotting  removal  action 
immediately.  Warfarin  takes  longer  to  start 
working. And also warfafin has more.severe 
adverse effects than heparin so warfarin is 
used  in  emergency  treatment  only
13. 
2. Thrombolytics 
Mainly used thrombolytics are of  
A. Streptokinase                                                        
B. Urokinase 
Clot dissolving medicines are not commonly 
used to treat PE .although they can quickly 
dissolve  a  clot.  Thrombolytics  also  greatly 
increase the risk of serious bleeding. so they 
are  occasionally  used  to  treat  a  life 
threatening PE. 
 
A. Streptokinase 
It  is  also  named  as  kabikinase  streptase. 
Acts  to  convert.plasminogen  to  plasmin. 
Plasmin degrades fibrin clots, fibrinogen and 
other plasma proteins.Increase in fibrinolytic 
activity  that  degrades  fibrinogen  levels  for 
24-36.hours takes place with IV in fusion of 
streptokinase.  
Adverse effect 
Chills, fever, skin rashes are frequent [20%]. 
Complications  may  include  purpurea, 
respiratory  di  stress  syndrome,  serum  sick 
ness,  vasculities,  renal  [or]..hepatic 
dysfunction
14. 
 
B. Urokinase 
It  is  also  be  named  as  abbokinase.  Direct 
plasminogen  activator  produced  by  human 
fetal kidney cells grown in culture. It acts on 
the  endogenous  fibrinolytic  system  and 
convert plasminogen to the enzyme plasmin 
which in turn degrades fibrin clots, fibrinogen 
and  other  plasma  proteins.  The  advantage 
of this agent is, a non antigenic. Urokinase is 
more expensive than streptokinase thus it is 
limitedly used one
14. 
 
Other treatment 
Inferior  vena  cava  [IVC]  filters  are  placed 
endovascular,  meaning  that  they  are 
inserted via the blood vessels. The choice of 
rate  depends  mainly  on  the  amount  of 
location of the blood clot within the venous 
system.  To  place  the  filter,  a  catheter  is 
guided  into  the    IVC  using  fluoroscopic 
guidance,  then  the  filter  is  pushed  through 
the catheter and developed into the desired 
location,  usually  just  below  the  junction  of 
the IVC and the lowest renal vein
16,17,18. 
 
Adverse effect 
Contrast allergy, renal insufficiency
16,17,18. 
 
ACUTE PULMONARY EMBOLISM 
Right  ventricular  dilation  in  the  setting  of 
acute  PE  is  associated  with  an  adverse 
prognosis.  The  effect  of  epoprostenol  was 
evaluated  on  the  right  ventricular  diameter 
and  function  in  patients  with  acute 
pulmonary embolism and right ventriculation 
dilatation. Pulmonary embolism is a frequent 
and  potentially  fat  disorder
19,20  an  acute 
increase in right ventricular after load is the 
hallmark  of  severe  pulmonary  embolism, 
and  is  responsible  for  many  of  its  clinical 
manifestations  and  complications.  The Int J Pharm Bio Sci 2012 Oct; 3(4): (P) 838 - 846 
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traditional  view  is  that  mechanical 
obstruction  by  thrombus  mass  causes 
pulmonary  hypertension
21.  Apart  from 
mechanical  obstruction,  vasoconstriction  of 
the pulmonary vasculature plays a pivotal in 
the acute rise in pulmonary arteries pressure 
in  patients  with  pulmonary  embolism
22. 
Studies  in  experimental  animal  models 
support  a  critical  role  for  pulmonary 
vasoconstriction  in  acute  pulmonary 
embolism
23,24.  In  animal  models  of  acute 
pulmonary  embolism  prostacyclin,  a 
relatively  selective  pulmonary  vasodilator, 
prevented  or  partially  reversed  the  rise  in 
pulmonary  vascular  resistance  and 
pressure
25,26.  However  the  potentially 
beneficial  role  of  pulmonary  vasodilator 
therapy  in  acute  pulmonary  embolism  has 
never been studied in a systematic way, 
A total 82 patients with pulmonary embolism 
as  diagnosed  by  spiral  CT,  were  screened 
for eligibility 
  
Adverse effect 
Two  patients  showed  facial  fleshing  during 
infusion with epoprostenal, however this was 
transient  and  did  not  influence  infusion 
rate
26. 
 
 
CONCLUSION 
 
Pulmonary embolism is the occlusion of one 
or more pulmonary arteries by thrombi that 
originate  else  where,  typically  in  the  large 
veins  of  the  lower  extremities  or  pelvis. 
Pulmonary  embolism  is  frequent  and 
potentially fatal disorder. The Risk factor and 
the condition that impair venous return, The 
condition  that  cause  endothelial  injury  or 
dysfunction,  and  underlying  hyper 
coagualable  states.  Symptoms  and  signs 
are  nonseptic  include  dyspena,  pleuritic 
chest  pain,  cough  syncope  or  cardio 
respiratory arrests tachypnea, tachhycardria, 
hypertension  and  a  loud  pulmonic 
component of the 2
nd heart sound.PE can be 
diagnosed  by  CT  angiogram, 
ventilation/perfusion.scan,pulmonary 
arteriogram,  
electrocardiogram(ECG),echocardiograph, 
ultrasonography, computed tomography lung 
scintigraphy.  Treatment  is  with 
anticoagulants  and  sometimes  clots 
dissolution  with  thrombolytics  or  surgical 
removal.  Preventive  measures  include 
anticoagulants  and  sometimes  insertion  of 
an  inferior  vena  cava  fitter.  The  use  of 
anticoagulants  and  thrombolytics  cause 
bleeding  disorder.  Anticoagulants  used  for 
primary  treatment  and  thrombolytics  are 
used  in  the  life  threatening  causes  only. 
Results of animal experiments studying the 
presence of pulmonary emboli are difficult to 
apply to humans. PE may account for 15% 
of all post operative deaths. leg amputation 
and  hip,  pelvic  and  spinal  surgery  are 
associated  with  highest  risk.  Fatal  events 
may  occurs  rarely,1-2  cases  per  100,000 
pregnancies  PE  increases  with  prolonged 
bed rest paralysis increase the risk. 
Further research should be performed 
on  the  contribution  of  process  of  care  and 
hospital  volume  and  physician  volume,  as 
well  as on the longitudinal trend of volume 
out comes correlations for patients with PE. 
Anticoagulation’s  control  can  be  improved 
when care is centralized at anticoagulation’s 
clinic. Programs should strive to coordinate 
care,  adopt  institution  and  region  wide 
guidelines  and  develop  and  implement 
appropriate  quality  of  care  programs. 
Patients  who  are  suspected  of  having 
pulmonary embolism begin their radio logic 
work  up  with  spiral  CT;  assuming  contrast 
injection is not contraindicated. if the spiral 
CT  is  negative  then  PE  is  excluded  if  the 
spiral CT is positive then the patient should 
be treated There are no data for the period 
following  hospital  discharge,  so  there  may 
have been patients in group who developed 
PE Subsequently.   
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